Institute of Cardiovascular Sciences, University College London, London, United Kingdom.
Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, United Kingdom.
J Am Heart Assoc. 2017 Oct 31;6(11):e006928. doi: 10.1161/JAHA.117.006928.
Genome-wide association studies identified ADAMTS7 as a risk locus for coronary artery disease (CAD). Functional studies suggest that ADAMTS7 may promote cellular processes in atherosclerosis. We sought to examine the association between genetic variation at ADAMTS7 and measures of atherosclerosis using histological, angiographic, and clinical outcomes data.
The lead CAD-associated single-nucleotide polymorphism rs3825807 at the ADAMTS7 locus was genotyped. The G allele (reduced ADAMTS7 function) was associated with a smaller fibrous cap (=0.017) and a smaller percentage area of α-actin (smooth muscle cell marker) in the intima (=0.017), but was not associated with calcification or plaque thickness, following ex vivo immunohistochemistry analysis of human coronary plaques (n=50; mean age 72.2±11.3). In two independent cohorts (Southampton Atherosclerosis Study [n=1359; mean age 62.5±10.3; 70.1% men] and the Emory Cardiovascular Biobank [EmCAB; n=2684; mean age 63.8±11.3; 68.7% men]), the G allele was associated with 16% to 19% lower odds of obstructive CAD (Southampton Atherosclerosis Study: odds ratio, 0.81; 95% confidence interval, 0.67-0.98; EmCAB: odds ratio, 0.84; 95% confidence interval, 0.75-0.95) with similar effects for multivessel, left anterior descending, and proximal CAD. Furthermore, each copy of the G allele was associated with lower angiographic severity Gensini score (Southampton Atherosclerosis Study, =0.026; EmCAB, <0.001), lower Sullivan Extent score (Southampton Atherosclerosis Study, =0.029; EmCAB, <0.001), and a 23% lower risk of incident revascularization procedures (EmCAB: hazard ratio, 0.76; 95% confidence interval, 0.59-0.98). There were no associations with all-cause mortality or incident myocardial infarction.
Genetic variation at the locus is associated with several complementary CAD phenotypes, supporting the emerging role of ADAMTS7 in atherosclerosis and may represent a potential drug target.
全基因组关联研究发现 ADAMTS7 是冠心病(CAD)的风险基因座。功能研究表明 ADAMTS7 可能促进动脉粥样硬化中的细胞过程。我们试图利用组织学、血管造影和临床结局数据,研究 ADAMTS7 基因变异与动脉粥样硬化程度之间的关系。
对 ADAMTS7 基因座上与 CAD 相关的先导单核苷酸多态性 rs3825807 进行了基因分型。G 等位基因(降低 ADAMTS7 功能)与纤维帽较小(=0.017)和内皮下α-肌动蛋白(平滑肌细胞标志物)的面积百分比较小有关(=0.017),但与钙化为或斑块厚度无关,这是通过对 50 例人冠状动脉斑块(平均年龄 72.2±11.3 岁)进行离体免疫组化分析得出的。在两个独立的队列中(南安普顿动脉粥样硬化研究 [n=1359;平均年龄 62.5±10.3;70.1%为男性] 和埃默里心血管生物库 [EmCAB;n=2684;平均年龄 63.8±11.3;68.7%为男性]),G 等位基因与阻塞性 CAD 的风险降低 16%至 19%有关(南安普顿动脉粥样硬化研究:比值比,0.81;95%置信区间,0.67-0.98;EmCAB:比值比,0.84;95%置信区间,0.75-0.95),且对多血管、前降支和近端 CAD 也有类似的效果。此外,每个 G 等位基因的拷贝与较低的血管造影严重程度 Gensini 评分(南安普顿动脉粥样硬化研究,=0.026;EmCAB,<0.001)、较低的 Sullivan 病变程度评分(南安普顿动脉粥样硬化研究,=0.029;EmCAB,<0.001)和血管重建程序的风险降低 23%有关(EmCAB:风险比,0.76;95%置信区间,0.59-0.98)。与全因死亡率或新发心肌梗死均无关联。
该基因座的遗传变异与多种互补的 CAD 表型相关,支持 ADAMTS7 在动脉粥样硬化中的新作用,并且可能代表潜在的药物靶点。